Key clinical point: The strategy of rapid alteration of drugs to overcome mutations conferring imatinib resistance in gastrointestinal stromal tumor (GIST) was feasible but ineffective.
Major finding: There were no objective responses among 12 patients treated with the strategy.
Study details: A phase Ib clinical trial in 12 patients with heavily pretreated metastatic GIST.
Disclosures: The study was supported by an ASCO Young Investigator Award, Pfizer, and Bayer. Dr. Serrano-Garcia disclosed honoraria from Bayer, a consulting or advisory role for Deciphera, research funding from Bayer and Deciphera, and travel accommodations and expenses from Pfizer.
Source: Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
This Week's Must Reads
Must Reads in GIST
Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.
Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Two novel TKIs better than one in GIST with multiple KIT mutations, Wagner AJ et al. ASCO 2018, Abstract 11509.
In GIST, KIT inhibitor may be of benefit in all post-imatinib lines of therapy, George S et al. ASCO 2018. Abstract 11511.
Sunitinib with regorafenib falls short for metastatic GIST, Serrano C et al. ASCO 2018 Abstract 11510.